$CERO 8-K/A SEC Filings

Phoenix Biotech Acquisition Corp. (“PBAX” and, after the Business Combination (as defined below), “New CERo”) is providing the following unaudited pro forma condensed combined financial information to aid you in your analysis of the fina...

Reference is hereby made to that certain Securities Purchase Agreement (the “Purchase Agreement”), dated February 5, 2024, by and between the undersigned investor (the “Investor”), Phoenix Biotech Acquisition Corp., a Delaware corporatio...

In connection with the approval of the Charter Amendment, holders of 523,341 shares of the Company’s Class A common stock, par value $0.0001 per share (“Class A Shares”), exercised redemption rights. As a result, following satisfaction o...